Market Overview

UPDATE: Wedbush Raises PT to $32 on Pacira Pharmaceuticals on Long-Term Outlook

Share:
Related PCRX
Mizuho: Pacira Pharma Has 'Forever' Potential, Stock Is A Buy
Mid-Afternoon Market Update: Dow Rises Over 100 Points; eBay Shares Drop On Disappointing Outlook
Many Growth Catalysts For Pacira (Seeking Alpha)

Wedbush maintained Pacira Pharmaceuticals (NASDAQ: PCRX) with an Outperform rating and raised the price target from $23.00 to $32.00.

Wedbush said, "As already preannounced, PCRX reported Q4 EXPAREL sales of $7.8MM, ahead of our original $7.0MM estimate. Q4 total revenues were $10.5MM and GAAP EPS loss was ($0.50) versus our ($0.32) and Street's ($0.42) estimates. The company ended Q4 with about $42.6MM in cash and including proceeds from the January convertible debt offering, we estimate current cash of about $123MM. We project runway well into potential profitability, which we model to occur in 2014."

Pacira Pharmaceuticals closed at $25.30 on Wednesday.

Latest Ratings for PCRX

DateFirmActionFromTo
Apr 2016Mizuho SecuritiesInitiates Coverage onBuy
Feb 2016Brean CapitalMaintainsBuy
Jan 2016JMP SecuritiesInitiates Coverage onMarket Outperform

View More Analyst Ratings for PCRX
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Price Target Analyst Ratings

 

Related Articles (PCRX)

View Comments and Join the Discussion!